1620291-95-3

Basic information

• Product Name: N-((5-((2-(6-(benzyloxy)pyridin-3-yl)phenoxy)methyl)-4,5-dihydroisoxazol-3-yl)methyl)imidazo[1,2-a]pyridine-6-carboxamide
• Synonyms: N-((5-((2-(6-(benzyloxy)pyridin-3-yl)phenoxy)methyl)-4,5-dihydroisoxazol-3-yl)methyl)imidazo[1,2-a]pyridine-6-carboxamide
• CAS NO: 1620291-95-3
• Molecular Weight: 533.586
• Mol File: 1620291-95-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-((5-((2-(6-(benzyloxy)pyridin-3-yl)phenoxy)methyl)-4,5-dihydroisoxazol-3-yl)methyl)imidazo[1,2-a]pyridine-6-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-((5-((2-(6-(benzyloxy)pyridin-3-yl)phenoxy)methyl)-4,5-dihydroisoxazol-3-yl)methyl)imidazo[1,2-a]pyridine-6-carboxamide(1620291-95-3)
• EPA Substance Registry System: N-((5-((2-(6-(benzyloxy)pyridin-3-yl)phenoxy)methyl)-4,5-dihydroisoxazol-3-yl)methyl)imidazo[1,2-a]pyridine-6-carboxamide(1620291-95-3)

Safety Data

• Hazardous Substances Data: 1620291-95-3(Hazardous Substances Data)

Upstream product

• 1620294-33-8 tert-butyl ((5-((2-(6-(benzyloxy)pyridin-3-yl)phenoxy)methyl)-4,5-dihydroisoxazol-3-yl)methyl)carbamate 
• 139022-25-6 imidazo[1,2-a]pyridine-6-carboxylic acid 
• 832735-54-3 2-(benzyloxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 
• 1620294-98-5 tert-butyl ((5-((2-bromophenoxy)methyl)-4,5-dihydroisoxazol-3-yl)methyl)carbamate 

Relevant articles and documents

4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS

The present invention provides substituted 4,5-dihydroisoxazole derivatives of formula (I), which may be therapeutically useful, more particularly NAMPT inhibitors and in which R1 R2, Y, X, "Het" and "p" have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPT) in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted 4,5-dihydroisoxazole derivatives of formula (I) or a pharmaceutically acceptable salts or stereoisomers or N-oxide thereof.